Mannose

Aethlon Medical, Inc. discusses its Hemopurifier device, designed to remove enveloped viruses like H5N1 from blood, with a study showing 99% removal in vitro. The device has been used in 38 patients for diseases like hepatitis C, HIV, COVID-19, and Ebola, and holds FDA Breakthrough Device designation for life-threatening viruses. Aethlon monitors Bird Flu cases and potential treatment needs.

New T-cell therapies and bispecific molecules are transforming cancer treatment, with FDA approval for small cell lung cancer. Research on myeloid-mediated immunotherapy resistance in prostate cancer and metabolic strategies to enhance CAR T-cell efficacy are also highlighted. Additional findings include methods to overcome T-cell exhaustion in solid tumors and novel statistical approaches to analyze tumor cell geometry.

Pregnant women at risk for sPTB will be randomized to receive synbiotics or placebo from 8-10 weeks gestation until delivery. The synbiotic contains eight Lactobacillus strains, inulin, FOS, and D-mannose. Adherence will be monitored via diaries, and standard care protocols for sPTB prevention will be followed. Primary outcomes include gestational age at delivery and PTB rates, with secondary outcomes covering neonatal and microbiome analyses.